- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04755205
Une étude d'histoire naturelle des enfants et des adultes atteints de neuroblastome olfactif
Background:
Olfactory neuroblastoma (ONB) is a rare cancer. It grows from tissue in the upper part of the nose cavity, related to the sense of smell and can affect a person s sense of smell. Researchers want to better understand the health problems of people with ONB. This may help them design better treatment and supportive care studies.
Objective:
To better understand ONB-the course of the disease, tumor characteristics, response to treatments, and management of the treatment.
Eligibility:
People ages 3 years and older who have ONB. They must enroll in NIH studies #19-C-0016 and #18-DC-0051.
Design:
Participants will be screened with a medical history and medical record review.
Participants do not have to visit NIH.
Participants will give a blood sample. They will complete surveys to assess their emotional and physical wellbeing and needs. Leftover tissue from biopsies and surgeries will be collected.
Participants will take smell tests. They will smell items and answer questions about them.
Participants may take taste tests. They will get plastic taste strips that they will move around their mouth to determine the taste.
Participants may have a physical exam. Their performance status may be assessed.
Participants may give blood, saliva, urine, and nasal secretion samples.
Participants may have computed tomography and/or magnetic resonance imaging scans.
Participants may have one or more tumor biopsies.
Participants will talk to the research team about the results of their medical record/tests evaluation. The team will recommend how to best manage and treat their disease.
Participants may give samples and complete surveys every 12 months. Their medical records will be reviewed every year. They will be monitored for the rest of their life.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Background:
Olfactory neuroblastoma (ONB), also known as esthesioneuroblastoma, is a malignant tumor of the nasal cavity believed to arise from the olfactory epithelium. ONB is rare, with a reported incidence of 0.4 per million (approximately 300 cases per year in the United States).
ONB most frequently arises in adults aged 20-60 years. Pediatric ONB is particularly rare, with only small case series or multi-institutional studies reported. However, a Surveillance Epidemiology and End Results (SEER) study of 47 pediatric patients with intranasal malignancy reported ONB as the most frequent pediatric intranasal malignancy (28%).
Due to the location of ONB in the sinonasal tract and anterior skull base, the presenting symptoms are often non-specific, including nasal obstruction and epistaxis, thus patients often present at advanced stages. Furthermore, ONB has a propensity for local invasion and relatively high rates of distant spread most commonly to the neck, lungs, and bones.
Clinical management in adults is generally surgical with adjuvant radiation.
The natural history of pediatric and adult ONB is incompletely understood, and treatment options for recurrent or metastatic ONB are limited. The planned natural history study as part of the NCI POB Rare Tumor Patient Engagement Network (RTPEN) will allow for comprehensive evaluation and recommendations to these patients while longitudinally collecting clinical, epidemiologic, and biological data.
Objective:
To characterize the natural history of ONB including clinical presentation, family history, patterns of disease progression, response to current treatment methods, disease recurrence, and overall survival
Eligibility:
Participants of age >= 3 years old with histologically documented ONB.
Design:
This protocol is intended to characterize the natural history of olfactory neuroblastoma.
Participants will undergo a comprehensive study entry evaluation including acquisition of imaging of tumor sites.
Medical histories will be documented, and participants followed throughout the course of their disease, with particular attention to patterns of disease recurrence and progression, response to therapies, duration of responses, and patient reported outcomes. Specimens will be obtained longitudinally, when feasible, and tumor growth rates will also be assessed throughout the course of the disease, when feasible.
Blood and tumor samples may be obtained at study entry and while on study.
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Marissa B Mallek, R.N.
- Numéro de téléphone: (240) 760-7498
- E-mail: marissa.mallek@nih.gov
Sauvegarde des contacts de l'étude
- Nom: Charalampos Floudas, M.D.
- Numéro de téléphone: (240) 474-1575
- E-mail: charalampos.floudas@nih.gov
Lieux d'étude
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20892
- Recrutement
- National Institutes of Health Clinical Center
-
Contact:
- For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
- Numéro de téléphone: 888-624-1937
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients with olfactory neuroblastoma.
La description
- INCLUSION CRITERIA:.
- Subjects with histologically documented olfactory neuroblastoma.
- Age >= 3 years old.
- Ability of subject to understand and the willingness to sign a written consent document
EXCLUSION CRITERIA:
Pregnant women are excluded from this study because of more than minimal risk activities (imaging studies with contrast, biopsies) pertaining to enrollment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Cohort 1
Subjects with confirmed olfactory neuroblastoma. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Characterize the natural history of ONB
Délai: duration of study
|
To characterize the natural history of ONB including clinical presentation, family history, patterns of disease progression, response to current treatment methods, disease recurrence, and overall survival. |
duration of study
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Charalampos Floudas, M.D., National Cancer Institute (NCI)
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système nerveux
- Tumeurs
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Tumeurs, neuroépithéliales
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs neuroectodermiques, primitives, périphériques
- Tumeurs neuroectodermiques primitives
- Maladies des nerfs crâniens
- Maladies des nerfs olfactifs
- Neuroblastome
- Esthésioneuroblastome, olfactif
Autres numéros d'identification d'étude
- 210009
- 21-C-0009
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@@@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.
Délai de partage IPD
Clinical data available during the study and indefinitely.@@@@@@@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.
Critères d'accès au partage IPD
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. @@@@@@@@@@@@Genomic data are made available via dbGaP through requests to the data custodians.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .